Status:
COMPLETED
Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Office of Rare Diseases (ORD)
National Center for Research Resources (NCRR)
Conditions:
Primary Ciliary Dyskinesia
Eligibility:
All Genders
5-18 years
Brief Summary
Mucociliary clearance, in which mucus secretions are cleared from the breathing airways, is the primary defense mechanism for the lungs. Inhaled particles, including microbes that can cause infections...
Detailed Description
PCD is a rare genetic disorder in which impaired mucus clearance commonly results in chronic cough and infections in the airways, sinuses, and middle ears. Long lasting airway infection ultimately lea...
Eligibility Criteria
Inclusion
- Diagnosis of PCD or probable PCD. More information about the criteria for a PCD diagnosis can be found in the protocol.
- Parent or guardian willing to provide informed consent
Exclusion
- Inability to attend follow-up appointments
- Previously received lung transplant
- Any disease that may have significant impact on lung function (e.g., severe congenital heart disease, severe scoliosis), respiratory infections (e.g., AIDS), or overall health status (e.g., cancer, end-stage kidney disease)
- Pregnant or breastfeeding
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00450918
Start Date
August 1 2006
End Date
August 1 2019
Last Update
October 7 2019
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital
Denver, Colorado, United States, 80218
2
Washington University
St Louis, Missouri, United States, 63130
3
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
4
Children's Hospital and Regional Medical Center
Seattle, Washington, United States, 98105